191 related articles for article (PubMed ID: 30316610)
21. Salvage treatment with low-dose weekly paclitaxel in elderly or poor performance status patients with metastatic urothelial carcinoma.
Han JJ; Kim YJ; Kim JW; Chang H; Lee JO; Lee KW; Jeong CW; Kim JH; Hong SK; Bang SM; Byun SS; Lee SE; Lee JS
Tumori; 2014; 100(4):439-45. PubMed ID: 25296594
[TBL] [Abstract][Full Text] [Related]
22. [Experience with combination chemotherapy consisting of methotrexate, vinblastine, adriamycin and cisplatin (M-VAC) in advanced urothelial cancer].
Nishio Y; Shirahase T; Shichiri Y; Habuchi T; Matsuda T; Nishimura K; Hida S; Okada Y; Yoshida O
Hinyokika Kiyo; 1988 Aug; 34(8):1371-5. PubMed ID: 3195405
[TBL] [Abstract][Full Text] [Related]
23. Outcomes With First-line PD-1/PD-L1 Inhibition in Advanced Urothelial Cancer: A Single Institution Experience.
Hsu MM; Xia Y; Troxel A; Delbeau D; Francese K; Leis D; Shepherd D; Balar AV
Clin Genitourin Cancer; 2020 Jun; 18(3):e209-e216. PubMed ID: 32253170
[TBL] [Abstract][Full Text] [Related]
24. Quality-of-life evaluation during platinum-based neoadjuvant chemotherapies for urothelial carcinoma.
Fukushi K; Narita T; Hatakeyama S; Yamamoto H; Soma O; Matsumoto T; Tobisawa Y; Yoneyama T; Imai A; Yoneyama T; Hashimoto Y; Koie T; Ohyama C
Int J Clin Oncol; 2017 Apr; 22(2):366-372. PubMed ID: 27933402
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of post-nephroureterectomy cisplatin-based adjuvant chemotherapy for locally advanced upper tract urothelial carcinoma: a multi-institutional retrospective study.
Nakagawa T; Komemushi Y; Kawai T; Otsuka M; Miyakawa J; Uemura Y; Kanatani A; Taguchi S; Naito A; Suzuki M; Nishimatsu H; Hirano Y; Tanaka Y; Matsumoto A; Miyazaki H; Fujimura T; Fukuhara H; Kume H; Igawa Y; Homma Y
World J Urol; 2017 Oct; 35(10):1569-1575. PubMed ID: 28397000
[TBL] [Abstract][Full Text] [Related]
26. Dual Checkpoint Inhibition with Ipilimumab plus Nivolumab After Progression on Sequential PD-1/PDL-1 Inhibitors Pembrolizumab and Atezolizumab in a Patient with Lynch Syndrome, Metastatic Colon, and Localized Urothelial Cancer.
Winer A; Ghatalia P; Bubes N; Anari F; Varshavsky A; Kasireddy V; Liu Y; El-Deiry WS
Oncologist; 2019 Nov; 24(11):1416-1419. PubMed ID: 31444293
[TBL] [Abstract][Full Text] [Related]
27. Impact of Primary Tumor Location on Survival from the European Organization for the Research and Treatment of Cancer Advanced Urothelial Cancer Studies.
Moschini M; Shariat SF; Rouprêt M; De Santis M; Bellmunt J; Sternberg CN; Tombal B; Collette L
J Urol; 2018 May; 199(5):1149-1157. PubMed ID: 29158104
[TBL] [Abstract][Full Text] [Related]
28. Comparative Study of the Safety and Efficacy of First-Line Cisplatin and Carboplatin Chemotherapy in Elderly Patients with Metastatic Urothelial Carcinoma.
Huang SY; Wu CC; Hsieh MC; Rau KM; Chiang PH; Sung MT; Luo HL; Huang CC; Huang CH; Liu JM; Su HY
Oncology; 2020; 98(3):146-153. PubMed ID: 31794969
[TBL] [Abstract][Full Text] [Related]
29. Emerging Role of Immunotherapy in Advanced Urothelial Carcinoma.
Koshkin VS; Grivas P
Curr Oncol Rep; 2018 Apr; 20(6):48. PubMed ID: 29644490
[TBL] [Abstract][Full Text] [Related]
30. Clinical and pathological evaluations of methotrexate, vinblastine, adriamycin and cisplatin chemotherapy for advanced urothelial cancers.
Ogawa T; Gotoh A; Takenaka A; Hara I; Gohji K; Arakawa S; Matsumoto O; Kamidono S
Cancer Chemother Pharmacol; 1992; 30 Suppl():S66-71. PubMed ID: 1394822
[TBL] [Abstract][Full Text] [Related]
31. Combination of docetaxel, ifosfamide and cisplatin (DIP) as a potential salvage chemotherapy for metastatic urothelial carcinoma.
Kakutani S; Fukuhara H; Taguchi S; Nagata M; Niimi A; Hattori M; Miyazaki H; Fujimura T; Nakagawa T; Kume H; Igawa Y; Homma Y
Jpn J Clin Oncol; 2015 Mar; 45(3):281-5. PubMed ID: 25425701
[TBL] [Abstract][Full Text] [Related]
32. Recent developments in the treatment of advanced bladder cancer.
Godwin JL; Hoffman-Censits J; Plimack E
Urol Oncol; 2018 Mar; 36(3):109-114. PubMed ID: 29395952
[TBL] [Abstract][Full Text] [Related]
33. Administration of cisplatin-based chemotherapy for advanced urothelial carcinoma in the community.
Sonpavde G; Watson D; Tourtellott M; Cowey CL; Hellerstedt B; Hutson TE; Zhan F; Vogelzang NJ
Clin Genitourin Cancer; 2012 Mar; 10(1):1-5. PubMed ID: 22340630
[TBL] [Abstract][Full Text] [Related]
34. First-line checkpoint inhibitors in PD-L1-positive patients with advanced urothelial carcinoma.
Tsimafeyeu I; Tjulandin S
BJU Int; 2019 Apr; 123(4):563-565. PubMed ID: 30457694
[No Abstract] [Full Text] [Related]
35. There and back again: An immunotherapy tale.
Guo Y; Krupnick AS
J Thorac Cardiovasc Surg; 2018 Apr; 155(4):1771-1774. PubMed ID: 29409610
[No Abstract] [Full Text] [Related]
36. From Clinical Trials to Real-life Clinical Practice: The Role of Immunotherapy with PD-1/PD-L1 Inhibitors in Advanced Urothelial Carcinoma.
Hussain SA; Birtle A; Crabb S; Huddart R; Small D; Summerhayes M; Jones R; Protheroe A
Eur Urol Oncol; 2018 Dec; 1(6):486-500. PubMed ID: 31158093
[TBL] [Abstract][Full Text] [Related]
37. Results of adjuvant chemotherapy for invasive urothelial cancer with lymph-node metastasis.
Kobayashi H; Obata K
Cancer Chemother Pharmacol; 1994; 35 Suppl():S14-7. PubMed ID: 7994781
[TBL] [Abstract][Full Text] [Related]
38. Paclitaxel Carboplatin chemotherapy as a second-line chemotherapy for advanced platinum resistant urothelial cancer in Japanese cases.
Soga N; Onishi T; Arima K; Sugimura Y
Int J Urol; 2007 Sep; 14(9):828-32. PubMed ID: 17760750
[TBL] [Abstract][Full Text] [Related]
39. Clinical outcome in patients with locally advanced bladder carcinoma treated with conservative multimodality therapy.
George L; Bladou F; Bardou VJ; Gravis G; Tallet A; Alzieu C; Serment G; Salem N
Urology; 2004 Sep; 64(3):488-93. PubMed ID: 15351577
[TBL] [Abstract][Full Text] [Related]
40. Prognostic Effect of FGFR Mutations or Gene Fusions in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Results from a Large, Single-institution Cohort.
Necchi A; Lo Vullo S; Raggi D; Gloghini A; Giannatempo P; Colecchia M; Mariani L
Eur Urol Focus; 2019 Sep; 5(5):853-856. PubMed ID: 29525380
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
